Showing results (1-10 of 409) with videos related to
Sort By:
Pageof 41
Current Opinion in Oncology|July 12, 2018
Hodgkin lymphoma in elderly patientsSven Borchmann, Andreas Engert, Boris BöllCurrent Opinion in Oncology|July 12, 2017
The genetics of Hodgkin lymphoma: an overview and clinical implicationsSven Borchmann, Andreas EngertScientific Reports|November 4, 2017
Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitudeSven Borchmann, Horst Müller, Andreas EngertCurrent Opinion in Oncology|July 26, 2016
Current developments in the treatment of early-stage classical Hodgkin lymphomaSven Borchmann, Bastian von Tresckow, Andreas EngertJournal of Clinical Medicine|April 3, 2021
Hodgkin Lymphoma-Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult PatientsJesko Momotow, Sven Borchmann, Dennis A Eichenauer, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 18, 2009
Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphomaKatrin S Reiners, Axel Gossmann, Elke Pogge von Strandmann, et al.European Journal of Haematology|September 3, 2022
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)Sarah Gillessen, Annette Pluetschow, Vladan Vucinic, et al.Blood|February 3, 2016
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trialsBoris Böll, Helen Goergen, Karolin Behringer, et al.Hemasphere|November 15, 2019
Suicide in European Hodgkin Lymphoma PatientsAustin I Kim, Helen Goergen, Andreas Engert, et al.Blood|May 10, 2005
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosisBoris Böll, Hinrich Hansen, Friederike Heuck, et al.Pageof 41